<DOC>
	<DOC>NCT01326858</DOC>
	<brief_summary>The purpose of this study is to assess the ocular comfort and safety of olopatadine hydrochloride opthalmic solution. 0.7%.</brief_summary>
	<brief_title>Safety and Comfort of AL-4943A Ophthalmic Solution</brief_title>
	<detailed_description>In this 3-treatment, 3-period, 6-sequence crossover study, each subject will receive all 3 products in randomized order, 1 product at a time, with a washout period of 24 hours between treatment periods. Following instillation of study medication, subjects will complete a 3-minute discomfort profile.</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis, Allergic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ketotifen</mesh_term>
	<mesh_term>Olopatadine Hydrochloride</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Able to be dosed in both eyes, to follow instructions, and willing and able to attend required study visits. Negative urine pregnancy test if female of childbearing potential and use adequate birth control throughout the study period. Other protocoldefined inclusion criteria may apply. History or clinical evidence of ocular herpes simplex or ocular herpes zoster infectious disease. History of any clinically significant external ocular disease within 30 days of the start of the study. Presence of active blepharitis, active meibomian gland dysfunction, active rosacea affecting the ocular surface/lid margin, active or chronic follicular conjunctivitis, preauricular adenopathy, or any other ocular or periocular abnormality that may affect the study outcomes. Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Ocular discomfort</keyword>
	<keyword>AL-4943A Ophthalmic Solution</keyword>
</DOC>